Gyre Therapeutics announced Q3 2026 revenue of $32.9 million and affirmed full-year guidance of $100.5 to $111 million. The company is advancing its protein degrader pipeline with planned Phase 2 and Phase 1 trials in 2027 and awaits a regulatory decision from China's NMPA on its drug F351 for liver fibrosis, expected in late 2026 or early 2027. Despite a net loss of $2.5 million in Q3, Gyre continues to grow its commercial products in China and invest in R&D for new therapies. The acquisition of Cullgen and ongoing clinical programs position Gyre for future growth in global biopharmaceutical markets.
Gyre Therapeutics reports Q3 2026 results and business updates. For readers following the health sector, here is Pluang's market snapshot as of Nov 06, 2026 04:11 WIB: Out of 150 priced US health stocks, 16 rose and 134 fell. Notable movers include CYTK at USD 55.45 with a -12.82% change and 100% buy orders, NUWE at USD 4.60 with a -12.71% change and 100% buy orders, and NUVB at USD 4.19 with a -11.42% change and nearly balanced buy/sell orders.
The 2026 Global Health Congress in New York gathered over 625 healthcare leaders from 25 countries to discuss innovation, equity, and investment in healthcare. The event featured 350+ startup applications in its Healthcare Shark Tank competition, cro...
Ambarella, an edge AI semiconductor company, announced its third quarter fiscal year 2027 earnings conference call will be held on November 24, 2026, at 1:30 p.m. Pacific Time. The company will release its earnings report after the market closes that...
Ademi LLP is investigating Strategic Education for potential securities fraud related to inaccurate statements about its financials and business operations, particularly in Australia. This probe follows a more than 20% decline in the company's stock ...
Corporate Insight released research identifying top financial firms leading in customer-facing AI tools, including virtual assistants and AI-powered fintech platforms. Fidelity and Voya lead in retirement plan virtual assistants, while Lively excels ...
A dormant Bitcoin wallet holding 8.18 BTC originally worth about $470 is now valued at approximately $660,000. Zhao Changpeng commented that Bitcoin is not just a store of value but continues to appreciate over time. This highlights Bitcoin's potenti...
